Skip to main content

Advertisement

SpringerLink
Log in

Aberrant expression of p27Kip1-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

We have previously reported that alterations of p27Kip1-interacting cell-cycle proteins frequently occur during the development of endometriosis-associated ovarian clear cell adenocarcinoma (CCA; Yamamoto et al., Histopathology in press, 20). However, CCA also occurs in association with clear cell adenofibroma (CCAF). In this study, the expressions of p27Kip1-interacting proteins, i.e., p27Kip1, Skp2, Cks1, cyclin A, cyclin E, and the Ki-67 labeling index (LI), were analyzed in 25 CCAFs (11 benign and 14 borderline) and 15 CCAF-associated CCAs, and compared with the expression status of each protein in the 23 previously studied endometriosis-associated CCAs. Although aberrant expression of all p27Kip1-interacting proteins was more frequent in the CCAF-associated CCAs than in the benign CCAFs, statistical significance was found only for Cks1 overexpression. The frequencies of p27Kip1 downregulation and overexpression of Skp2 and cyclin A were significantly lower in CCAF-associated than in endometriosis-associated CCAs (P < 0.05, respectively). The frequencies of p27Kip1 downregulation and Skp2 overexpression in borderline CCAFs were significantly lower than those in atypical endometriosis components in endometriosis-associated CCAs (P < 0.05, respectively). Mean Ki-67 LI increased significantly through benign (4.9%) to borderline (11.1%) CCAF and to CCAF-associated CCA (30.6%), but the latter two values were significantly lower than those in atypical endometriosis (21.4%) and endometriosis-associated CCA (46.9%; P < 0.05, respectively). These data suggest that accumulated alterations of p27Kip1-interacting proteins may accelerate the development of CCAs regardless of their carcinogenetic pathways, but that tumor cells in the CCAF-associated pathway appear to show slower cell-cycle progression than those in the endometriosis-associated pathway, possibly accounting for the distinct clinicopathological features of the two CCA subtypes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Seidman JD, Russell P, Kurman RJ (2001) Surface epithelial tumors of the ovary. In: Kurman RJ (ed) Blaustein's pathology of the female genital tract, 5th edn. Springer-Verlag, New York, pp 791–904

    Google Scholar 

  2. Sugiyama T, Kamura T, Kigawa J et al (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88:2584–2589

    Article  CAS  PubMed  Google Scholar 

  3. Ikeda K, Sakai K, Yamamoto R et al (2003) Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer. Int J Gynecol Cancer 13:776–784

    Article  CAS  PubMed  Google Scholar 

  4. Tavassoli FA, Devilee P (eds) (2003) World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon

    Google Scholar 

  5. Kaku T, Ogawa S, Kawano Y et al (2003) Histological classification of ovarian cancer. Med Electron Microsc 36:9–17

    Article  PubMed  Google Scholar 

  6. Gynecologic cancer committee, Japan society of obstetrics and gynecology (2008) Annual report of gynecological cancer patients in Japan 2006. Acta Obstet Gynaecol Jpn 60:1001–1085 in Japanese

    Google Scholar 

  7. Takano M, Sugiyama T, Yaegashi N et al (2008) Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer 18:937–942

    Article  CAS  PubMed  Google Scholar 

  8. Takano M, Kikuchi Y, Yaegashi N et al (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94:1369–1374

    Article  CAS  PubMed  Google Scholar 

  9. Sampson JA (1925) Endometrial carcinoma of the ovary arising in endometrial tissue in that organ. Arch Surg 10:1–72

    Google Scholar 

  10. Vercellini P, Parazzini F, Bolis G et al (1993) Endometriosis and ovarian cancer. Am J Obstet Gynecol 169:181–182

    CAS  PubMed  Google Scholar 

  11. Fukunaga M, Nomura K, Ishikawa E et al (1997) Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 30:249–255

    Article  CAS  PubMed  Google Scholar 

  12. Ogawa S, Kaku T, Amada S et al (2000) Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol 77:298–304

    Article  CAS  PubMed  Google Scholar 

  13. LaGrenade A, Silverberg SG (1988) Ovarian tumors associated with atypical endometriosis. Hum Pathol 19:1080–1084

    Article  CAS  PubMed  Google Scholar 

  14. Mostoufizadeh M, Scully RE (1980) Malignant tumors arising in endometriosis. Clin Obstet Gynecol 23:951–963

    Article  CAS  PubMed  Google Scholar 

  15. Seidman JD (1996) Prognostic importance of hyperplasia and atypia in endometriosis. Int J Gynecol Pathol 15:1–9

    Article  CAS  PubMed  Google Scholar 

  16. Varma R, Rollason T, Gupta JK et al (2004) Endometriosis and the neoplastic process. Reproduction 127:293–304

    Article  CAS  PubMed  Google Scholar 

  17. Jiang X, Hitchcock A, Bryan EJ et al (1996) Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res 56:3534–3539

    CAS  PubMed  Google Scholar 

  18. Jiang X, Morland SJ, Hitchcock A et al (1998) Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 58:1707–1712

    CAS  PubMed  Google Scholar 

  19. Sato N, Tsunoda H, Nishida M et al (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60:7052–7056

    CAS  PubMed  Google Scholar 

  20. Yamamoto S, Tsuda H, Miyai K, et al (2009) Cumulative alterations of p27Kip1-related cell cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinoma. Histopathology (in press)

  21. Bell DA, Scully RE (1985) Benign and borderline clear cell adenofibromas of the ovary. Cancer 56:2922–2931

    Article  CAS  PubMed  Google Scholar 

  22. Roth LM, Langley FA, Fox H et al (1984) Ovarian clear cell adenofibromatous tumors. Benign, of low malignant potential, and associated with invasive clear cell carcinoma. Cancer 53:1156–1163

    Article  CAS  PubMed  Google Scholar 

  23. Yamamoto S, Tsuda H, Yoshikawa T et al (2007) Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics. Am J Surg Pathol 31:999–1006

    Article  PubMed  Google Scholar 

  24. Yamamoto S, Tsuda H, Takano M et al (2008) Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative ovarian clear-cell carcinogenic pathway. J Pathol 216:103–110

    CAS  PubMed  Google Scholar 

  25. Yamamoto S, Tsuda H, Takano M et al (2008) Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors. Mod Pathol 21:115–124

    CAS  PubMed  Google Scholar 

  26. Filipits M, Puhalla H, Wrba F (2003) Low p27Kip1 expression is an independent prognostic factor in gallbladder carcinoma. Anticancer Res 23:675–679

    CAS  PubMed  Google Scholar 

  27. Hui AM, Li X, Shi YZ, Torzilli G, Takayama T, Makuuchi M (2000) p27(Kip1) expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: association with cancer progression and prognosis. Hepatology 31:1068–1072

    Article  CAS  PubMed  Google Scholar 

  28. Huang HY, Kang HY, Li CF et al (2006) Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas. Clin Cancer Res 12:487–498

    Article  CAS  PubMed  Google Scholar 

  29. Li SH, Li CF, Sung MT et al (2007) Skp2 is an independent prognosticator of gallbladder carcinoma among p27(Kip1)-interacting cell cycle regulators: an immunohistochemical study of 62 cases by tissue microarray. Mod Pathol 20:497–507

    Article  CAS  PubMed  Google Scholar 

  30. Zhang H, Kobayashi R, Galaktionov K, Beach D (1995) p19skp1 and p45skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 82:915–925

    Article  CAS  PubMed  Google Scholar 

  31. Gstaiger M, Jordan R, Lim M et al (2001) Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 98:5043–5048

    Article  CAS  PubMed  Google Scholar 

  32. Chao Y, Shih Y-L, Chiu J-H et al (1998) Overexpression of cyclin A but not Skp2 correlated with the tumor relapse of human hepatocellular carcinoma. Cancer Res 58:985–990

    CAS  PubMed  Google Scholar 

  33. Latres E, Chiarle R, Schulman BA et al (2001) Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci USA 98:2515–2520

    Article  CAS  PubMed  Google Scholar 

  34. Shigemasa K, Gu L, O'Brien TJ, Ohama K (2003) Skp2 expression is a prognostic factor in patients with ovarian adenocarcinoma. Clin Cancer Res 9:1756–1763

    CAS  PubMed  Google Scholar 

  35. Sui L, Dong Y, Watanabe Y et al (2006) Clinical significance of Skp2 expression, alone and combined with Jab1 and p27 in epithelial ovarian tumors. Oncol Rep 15:765–771

    CAS  PubMed  Google Scholar 

  36. Itamochi H, Kigawa J, Sugiyama T et al (2002) Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100:281–287

    Article  PubMed  Google Scholar 

  37. Shimizu M, Nikaido T, Toki T, Shiozawa T, Fujii S (1998) Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 85:669–677

    Article  Google Scholar 

  38. Hwang HC, Clurman BE (2005) Cyclin E in normal and neoplastic cell cycles. Oncogene 24:2776–2786

    Article  CAS  PubMed  Google Scholar 

  39. Nakayama KI, Hatakeyama S, Nakayama K (2001) Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1. Biochem Biophys Res Commun 282:853–860

    Article  CAS  PubMed  Google Scholar 

  40. Anttila MA, Kosma V-M, Hongxiu J et al (1999) p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer 79:1870–1878

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by a grant-in-aid for promotion of defense medicine from the Ministry of Defense, Japan (S.Y., H.T., and O.M.), and by a grant-in-aid for cancer research from the Ministry of Health, Labour, and Welfare, Japan (H.T.). The authors are thankful to Ms. Kozue Suzuki for technical assistance with immunohistochemistry.

Conflict of interest statement

The authors declare no actual or potential conflicts of interest in this study.

Author information

Authors and Affiliations

  1. Department of Basic Pathology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan

    Sohei Yamamoto, Hitoshi Tsuda, Kosuke Miyai & Osamu Matsubara

  2. Department of Obstetrics and Gynecology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan

    Masashi Takano

  3. Department of Laboratory Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan

    Seiichi Tamai

  4. Pathology Section, Clinical Laboratory Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Tokyo, 104-0045, Japan

    Hitoshi Tsuda

Authors
  1. Sohei Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hitoshi Tsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kosuke Miyai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masashi Takano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Seiichi Tamai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Osamu Matsubara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hitoshi Tsuda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamamoto, S., Tsuda, H., Miyai, K. et al. Aberrant expression of p27Kip1-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways. Virchows Arch 455, 413–422 (2009). https://doi.org/10.1007/s00428-009-0844-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-009-0844-5

Keywords

Search

Navigation